Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What is the Anticipated CAGR of the Diabetic Macular Edema (DME) Market, and What Factors Will Drive It?

The market for diabetic macular edema (DME) has experienced consistent growth in recent years. The market is set to increase from $4.67 billion in 2024 to $4.89 billion in 2025, with a compound annual growth rate (CAGR) of 4.7%. Factors contributing to the growth in the past included an upturn in diabetes cases, a rise in edema-related disorders, an increase in diabetic eye diseases, a boost in the elderly population, and higher instances of blindness.

Over the next few years, the market for diabetic macular edema (DME) is poised for steady expansion, with projections placing it at $5.82 billion in 2029, boasting a compound annual growth rate (CAGR) of 4.4%. Factors contributing to this predicted growth during the forecast period include improved accessibility to healthcare, increasing governmental healthcare support, growing awareness of diabetic complications, increased reliance on telemedicine for eye care services, and the proliferation of specialized centers offering diabetic eye care. Key trends anticipated during the forecast period encompass the development of anti-VEGF therapies, the use of corticosteroid implants, enhancements in drug delivery systems, innovations in retinal laser procedures, the use of AI in diagnosis tools, and the shift towards minimally invasive surgical procedures.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21169&type=smp

Which Primay Drivers Are Accelerating Growth in the Diabetic Macular Edema (DME) Market?

The expected growth in the diabetic macular edema (DME) market is primarily driven by the escalating incidence of diabetes worldwide. Factors contributing to the surge in diabetes include inactive lifestyles, unhealthy eating habits, increasing rates of obesity, aging populations, and genetic factors. Retinal blood vessels get harmed due to diabetes, causing diabetic macular edema through fluid leakage into the macula causing swelling. The US-based public health research institute, the Institute for Health Metrics and Evaluation, stated in June 2023 that more than half a billion people around the world were suffering from diabetes. This figure is anticipated to more than double, hitting 1.3 billion people by 2050. Hence, the growing occurrence of diabetes is propelling the expansion of the diabetic macular edema (DME) market.

Which Primary Segments of the Diabetic Macular Edema (DME) Market Are Driving Growth and Industry Transformations?

The diabetic macular edema (DME) market covered in this report is segmented –

1) By Treatment: Anti-VEGF Therapy, Corticosteroids, Laser Therapy, Surgical Intervention

2) By Disease Stage: Early Stage, Moderate Stage, Advanced Stage

3) By Patient Demographics: Adults, Elderly, Children

4) By Route Of Administration: Intravitreal Injection, Topical, Systemic

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Anti-VEGF Therapy: Monoclonal Antibodies, Recombinant Protein-Based Therapies

2) By Corticosteroids: Intravitreal Steroid Injections, Injectable Sustained-Release Corticosteroids

3) By Laser Therapy: Focal Laser Photocoagulation, Panretinal Photocoagulation

4) By Surgical Intervention: Vitrectomy, Membrane Peeling

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21169&type=smp

Which Regions Are Key Players in the Growth of the Which Primay Drivers Are Accelerating Growth in the Diabetic Macular Edema (DME) Market? Market?

North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (DME) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Diabetic Macular Edema (DME) Industry Dynamics?

Significant businesses engaged in the diabetic macular edema (DME) therapy sector are concentrating on progressing technology, such as avant-garde drug treatments, to enhance the management and outcome for patients. These cutting-edge treatments leverage fresh research and novel technologies to better tackle complex health conditions. The therapies aim to boost their efficiency, minimize adverse effects, and deliver superior patient outcomes. For instance, in March 2022, Novartis AG, a pharmaceutical company headquartered in Switzerland, declared that the European Commission approved Beovu for the treatment of visual impairment due to diabetic macular edema (DME). This approval centered on results from Phase III KESTREL and KITE studies, which illustrated how Beovu’s effectiveness matched up with aflibercept in boosting vision over a year. Importantly, the majority of the patients treated with Beovu adhered to a 12-week treatment plan, experiencing fewer incidents of retinal fluid compared to those treated with aflibercept.

View the full report here:

https://www.thebusinessresearchcompany.com/report/diabetic-macular-edema-dme-global-market-report

What Parameters Are Used to Define the Diabetic Macular Edema (DME) Market?

Diabetic macular edema (DME) is a complication of diabetes that occurs when fluid accumulates in the macula, the central part of the retina responsible for sharp vision. This swelling is caused by damaged blood vessels leaking fluid and proteins into the retinal tissue, leading to vision impairment or blindness if left untreated. DME is a common cause of vision loss in diabetic patients and is associated with diabetic retinopathy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21169

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model